BiomX

Company Overview

Snapshot

Founded in May 2015 by Eran Elinav, Rotem Sorek, and Tim Lu, BiomX operates with 51–200 employees. The company has raised a total of $146.5M across 11 funding rounds from 15 investors. In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform, expanding its presence in security and defense markets.

Business overview

BiomX is a clinical-stage microbiome company specializing in developing natural and engineered phage cocktails to target and destroy bacteria in the treatment of chronic diseases. Its core technology leverages computational and synthetic biology to discover and validate proprietary bacterial targets and customize phage compositions. The company serves the health tech and life sciences sectors, focusing on conditions such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX also aims to expand into security and defense markets through its X Security & Defense division, identifying and commercializing technologies for national security, emergency response, and critical infrastructure protection.

Strategic signal

In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform. This strategic move signals BiomX's intent to diversify beyond its core microbiome therapies into the security and defense sectors, leveraging AI to address evolving operational needs in national security, emergency response, and critical infrastructure protection. This expansion indicates a significant strategic pivot and potential new revenue streams for the company.

Company Intelligence Q&A

What was a significant acquisition made by BiomX in 2026?

In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform, to expand its presence in security and defense markets.

What was the outcome of BiomX's Phase 1b/2a trial for BX004 in cystic fibrosis patients?

In November 2023, BiomX announced positive topline results from Part 2 of the Phase 1b/2a trial evaluating BX004 for the treatment of chronic pulmonary infections in patients with cystic fibrosis.

What was a key development regarding BiomX's BX004 program in October 2025?

In October 2025, BiomX provided a program update and announced new FDA feedback that could potentially expand the development pathways for BX004.

When did BiomX merge with Chardan Healthcare Acquisition Corp.?

In October 2019, Chardan Healthcare Acquisition Corp. completed its merger with BiomX Ltd., leading to BiomX becoming a public company.

What was a recent financial event for BiomX in 2025?

In February 2025, BiomX announced a series of financings for aggregate gross proceeds, with participation from Deerfield Management.